Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915


Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 10/15 11:09:59 am
355.15 DKK   +0.20%
10/14NOVO NORDISK : A/S – Share repurchase programme
10/14NOVO NORDISK : Disclosure of transaction data
10/08NOVO NORDISK : MIT - New capsule can orally deliver drugs that usually have to be injected
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : purchases B shares worth DKK 2,235 million from Novo Holdings A/S under the 2019 share repurchase programme

share with twitter share with LinkedIn share with facebook
share via e-mail
05/07/2019 | 03:21pm EDT

Bagsværd, Denmark, 7 May 2019 - Novo Nordisk A/S has today entered into an agreement to purchase 7,012,500 B shares of DKK 0.20 to a value of DKK 2,235 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S' 2019 share repurchase programme of up to a total of DKK 15 billion to be executed during a 12-month period beginning 1 February 2019. The transaction price is DKK 318.71 per share and has been calculated as the three-day volume weighted average market price from 3 May to 7 May 2019 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Prior to the sale of B shares, Novo Holdings A/S' ownership of Novo Nordisk A/S was 28.6% of the share capital and 76.3% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 142,776,500 B shares of DKK 0.20, corresponding to 28.3% of the capital and 76.2% of the votes in Novo Nordisk A/S.

The transaction is in line with the announcement on 3 May 2019 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S' share capital around 28%.

With the transaction stated above, Novo Nordisk A/S owns a total of 22,369,001 B shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 of DKK 0.20 including treasury shares.

About Novo Holdings A/S
Novo Holdings
is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation's assets.

In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets.

It is the vision of Novo Holdings to be recognized as a world-leading life science investor with a focus on creating long-term value. Read more at www.novo-holdings.dk.

About Novo Nordisk A/S
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information
Novo Holdings Communication

Christian Mostrup Scheel +45 3067 4805 cims@novo.dk

Novo Nordisk Media:

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com

Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com

Novo Nordisk Investors:

Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com

Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com

Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com

Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com

 Company announcement No 31/2019


This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire

© InPublic, source European Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK AS
10/15Factbox - How are businesses preparing for a 'no-deal Brexit'?
10/14NOVO NORDISK : A/S – Share repurchase programme
10/14NOVO NORDISK : Disclosure of transaction data
10/09NOVO NORDISK : Department of Health, KP and Novo Nordisk announces the launch of..
10/09NOVO NORDISK : K-P CM inaugurates mobile diabetic clinic
10/08NOVO NORDISK : MIT - New capsule can orally deliver drugs that usually have to b..
10/07NOVO NORDISK : Disclosure of transaction data
10/07NOVO NORDISK A/S : – Share repurchase programme
10/04UNIVERSITY OF BIRMINGHAM : New partnership aims to identify new disease mechanis..
10/04EUROPE MARKETS: Defensive Plays Nudge European Stocks Higher As Key Jobs Data..
More news
Financials (DKK)
Sales 2019 121 B
EBIT 2019 52 749 M
Net income 2019 39 101 M
Finance 2019 11 395 M
Yield 2019 2,38%
P/E ratio 2019 21,6x
P/E ratio 2020 18,7x
EV / Sales2019 6,74x
EV / Sales2020 6,31x
Capitalization 826 B
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 367,82  DKK
Last Close Price 355,15  DKK
Spread / Highest target 26,7%
Spread / Average Target 3,57%
Spread / Lowest Target -37,2%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS16.53%122 098
JOHNSON & JOHNSON1.77%344 992
ROCHE HOLDING AG18.86%247 003
MERCK AND COMPANY10.84%216 838
PFIZER-16.84%200 777
NOVARTIS16.69%197 613